Ionis Pharmaceuticals, Inc.
IONS
$75.83
$0.450.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.06B | 943.71M | 966.96M | 944.05M | 717.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.06B | 943.71M | 966.96M | 944.05M | 717.25M |
| Cost of Revenue | 942.46M | 931.53M | 893.25M | 893.99M | 898.60M |
| Gross Profit | 115.73M | 12.18M | 73.71M | 50.07M | -181.35M |
| SG&A Expenses | 467.98M | 393.87M | 351.76M | 316.59M | 291.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.41B | 1.33B | 1.25B | 1.21B | 1.19B |
| Operating Income | -352.25M | -381.69M | -278.05M | -266.52M | -472.43M |
| Income Before Tax | -325.09M | -379.60M | -258.72M | -274.43M | -464.16M |
| Income Tax Expenses | 1.89M | 1.79M | -2.38M | -6.22M | -6.13M |
| Earnings from Continuing Operations | -326.98 | -381.39 | -256.34 | -268.22 | -458.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -326.98M | -381.39M | -256.34M | -268.22M | -458.03M |
| EBIT | -352.25M | -381.69M | -278.05M | -266.52M | -472.43M |
| EBITDA | -338.65M | -369.24M | -266.80M | -255.17M | -460.86M |
| EPS Basic | -2.01 | -2.37 | -1.61 | -1.76 | -2.99 |
| Normalized Basic EPS | -1.32 | -1.45 | -1.05 | -1.04 | -1.86 |
| EPS Diluted | -2.08 | -2.45 | -1.69 | -1.83 | -2.99 |
| Normalized Diluted EPS | -1.39 | -1.52 | -1.12 | -1.11 | -1.86 |
| Average Basic Shares Outstanding | 645.78M | 639.64M | 635.64M | 624.47M | 611.29M |
| Average Diluted Shares Outstanding | 668.97M | 662.83M | 658.83M | 647.66M | 611.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |